Since inception, VEG has conducted over 22 epigenetic clinical trials accruing over 400 patients to novel trials and has leveraged over $12 million of funding from peer-reviewed grants, philanthropy and industry. VEG has published over 50 peer-reviewed publications and numerous presentations to scientific bodies and community groups.

VEG have successfully partnered with the Victorian Cancer Agency, the Snowdome Foundation, external collaborators and industry and purposefully engaged with the community to raise funds for, and increase awareness of, blood cancers and epigenetics, and ultimately improved treatments for patients with blood cancers.

Funding History Major grants

Date Description Funding Body Amount
2009 – 2012 VEG1 VCA $2.3M
2011 – 2013 Research Nurse VCA $0.25M
2012 – 2014 VEG Capacity Building 1 Snowdome $0.8M
2014 – 2017 VEG2 VCA $3M
2014 – 2017 VEG Capacity Building 2 Snowdome $0.86M


During the 6 years of VEG, our investigators have:

  • published over 53 peer review journal articles
  • published 7 book chapters
  • presented 22 conference abstracts
  • been invited to speak at national and international scientific meetings on 48 occasions.

Select VEG Publications, for a more comprehensive list please contact VEG for details.

  • L Ellis, Y Pan, GK Smyth, DJ George, LC McCormack, R Williams-Truax, P Atadja, C Zhao, M Dugan, K Culver, R Johnstone, HM Prince. The histone deacetylase inhibitor LBH589 induces responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. Clinical Cancer Research 2008; 14: 4500-4510 [IF:6.177] Citations= 217 <read more…>

– First publication to demonstrate in vivo gene expression changes with HDACi and highly sited for this

  • S Arulogun, HM Prince, J Ng, S Lade, G Ryan, O Blewitt, C McCormack. Long term outcomes of patients with advanced-stage cutaneous T cell lymphoma and large cell transformation. Blood 2008 15;112(8):3082-7. [IF:10.896] Citations = 71 <read more…>

–  High impact journal demonstrating key prognostic factors for skin lymphoma outcomes

  • A Spencer, HM Prince, AW Roberts, IW Prosser, KF Bradstock, L Coyle, DS Gill, N Horvath, J Reynolds, N Kennedy. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation (ASCT) procedure. Journal Clinical Oncology 2009 27:1788-1793, 2009 [IF:18.970] Citations = 285 <read more…>

– Highly sighted collaborative group study supporting maintenance therapy in myeloma

  • RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, HM Prince, JP Leonard, LJ Geskin, C Reeder, D Joske, WD Figg, ER Gardner, SM Steinberg, E Jaffe, M Stetler-Stevenson, A Tito Fojo, SE Bates. A Multi-Institutional Phase II Trial of the HDAC Inhibitor Romidepsin as Monotherapy for Patients with Cutaneous T-cell Lymphoma. Journal Clinical Oncology 2009: 27; 5410-7 [IF:18.970]) Citations = 366 <read more…>

– Highly sited study of this HDACi for CTCL. Led to the drugs approval in US, Europe and Australia. Led to ongoing collaborations with NCI group

  • HM Prince, M. Duvic, A Martin, W Sterry, C Assaf, A Negro-Vilar, Y Sun, D Straus, M Acosta. Phase 3 Placebo-Controlled Trial of Denileukin Diftitox for Patients With Primary Cutaneous T-Cell Lymphoma. Journal Clinical Oncology 2010; 28: 1870-1877[IF:18.970] Citations = 113 <read more…>

– Largest Phase III study of advanced stage CTCL ever reported

  • MJ Bishton, HM Prince, SJ Harrison, BP Martin, N McLaughlin, J Chloe, EC Josefsson, KJ Henley, BT Kile, RW Johnstone. Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011, 117: 3658-3668 [IF:10.896] Citations = 56 <read more…>

– First study examining the mechanism of action of a key effect of HDACi on megakaryocytes

  • RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, E Jaffe, A Ling, M Turner, C Peer, WD Figg, SM Steinberg, S Smith, D Joske, I Lewis, L Hutchins, Ml Craig, A Tito Fojo, JJ Wright, SE Bates. Phase II Trial of Romidepsin in Patients with Peripheral T-cell Lymphoma. Blood 2011; 117: 5827-34 [IF:10.896] Citations = 204 <read more…>

– Major patient contributor and study design involvement for this highly sited study of this HDACi for PTCL. Led to the drugs approval in US, Europe and Australia

  • SJ Harrison, H Quach, E Link, J Dean, S Ruell, JF Seymour, H Januszewicz, DS Ritchie, R Johnstone, P Neeson, M Dickinson, J Nichols, HM Prince. A High Rate Of Durable Responses with Romidepsin, Bortezomib And Dexamethasone In Relapsed or Refractory Multiple Myeloma. Blood 2011; 118: 6274-83 [IF:10.896] Citations = 47 <read more…>

– High impact journal and the first published study combining an HDACi with a proteasome inhibitor. Performed in Melbourne alone

  • B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, P Borchmann, F Morschhauser, M Wilhelm, L Pinter-Brown, S Padmanabhan, A Shustov, J Nichols, S Carroll, J Balser, S Horwitz. Results From a Pivotal, Open-Label, Phase 2 Study of Romidepsin in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy. Journal Clinical Oncology 2012; 30: 631-636 [IF:18.970] Citations = 167 <read more…>

– Highly sited study of this HDACi for PTCL. Led to the drugs approval in US, Europe and Australia

  • DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, M Shin, DM Wall, D Hönemann, P Gambell, DA Westerman, J Haurat, JA Westwood, AM Scott, L Kravets, M Dickinson, JA Trapani, MJ Smyth, PK Darcy, MH Kershaw, HM Prince. Persistence and efficacy of second generation CAR-T cell against the LeY antigen in acute myeloid leukemia. Molecular Therapy 2013 [IF:6.873] Citations = 37 <read more…>

– The first chimeric T cell receptor study reported for AML. Led to involvement of further clinical trials with Novartis of CAR-T cells in ALL and CLL